|
Sep 3
|
RegenxBio touts positive data for rare disease drug RGX-121
|
|
Sep 3
|
REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect
|
|
Jul 25
|
REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights
|
|
Jul 12
|
Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?
|
|
Jul 8
|
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
|
|
Jun 24
|
REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients
|
|
Jun 21
|
Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy
|
|
Jun 21
|
FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
|
|
Jun 18
|
REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II
|
|
Jun 18
|
Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short
|
|
May 11
|
Analysts Have Lowered Expectations For REGENXBIO Inc. (NASDAQ:RGNX) After Its Latest Results
|
|
May 10
|
Regenxbio Inc (RGNX) Q1 2024 Earnings: Misses Analyst Revenue and EPS Forecasts
|
|
May 9
|
REGENXBIO Inc. (NASDAQ:RGNX) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Q1 2024 Regenxbio Inc Earnings Call
|
|
May 9
|
Regenxbio Inc (RGNX) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress and Robust ...
|
|
May 8
|
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
|
|
May 8
|
REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
|
|
May 1
|
REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
|
|
Apr 24
|
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
|
|
Apr 17
|
REGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measures
|